Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash from Investing Activities data on file, last reported at $94.5 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 403.84% year-over-year to $94.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $331.0 million (down 13.62% YoY) and the FY2025 annual result came in at $255.3 million, up 387.62% from the prior year.
• Cash from Investing Activities grew to $94.5 million in Q1 2026 per DNLI's latest filing, from $20.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $172.2 million in Q4 2024 and bottomed at -$453.2 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $73.0 million (2023), against an average of $21.7 million.
• The widest annual swing landed in 2023, when Cash from Investing Activities soared 554.45%; it then tumbled 388.8% in 2024.
• Tracing DNLI's Cash from Investing Activities over 5 years: stood at -$127.6 million in 2022, then surged by 157.27% to $73.0 million in 2023, then soared by 135.75% to $172.2 million in 2024, then plunged by 87.94% to $20.8 million in 2025, then jumped by 354.83% to $94.5 million in 2026.
• Per Business Quant, the three latest DNLI Cash from Investing Activities figures stand at $94.5 million (Q1 2026), $20.8 million (Q4 2025), and $57.8 million (Q3 2025).

Peer Comparison